Inhibition of the pro-inflammatory mediators' production and anti-inflammatory effect of the iridoid scrovalentinoside.
We have studied scrovalentinoside, an iridoid with anti-inflammatory properties isolated from Scrophularia auriculata ssp. pseudoauriculata, as an anti-inflammatory agent in different experimental models of delayed-type hypersensitivity. We found that scrovalentinoside reduced the edema induced by oxazolone at 0.5 mg/ear and sheep red blood cells at 10 mg/kg. The observed effect occurred during the last phase or inflammatory response; during the earlier phase or induction of the delayed-type hypersensitivity reaction, no significant activity was noted. Thus, scrovalentinoside reduced both the edema and cell infiltration in vivo and reduced lymphocyte proliferation in vitro, affecting the cycle principally during the first 48 h. Whereas cells stimulated with phytohemagglutinin changed from the G(0)/G(1) phase to the S and G(2)/M phases, when these same cells were treated with scrovalentinoside (100 microM), they remained in the G(0)/G(1) phase. Finally, scrovalentinoside inhibited the production of the pro-inflammatory mediators' TNF-alpha, IFN-gamma, IL-1beta, IL-2, IL-4, LTB(4), and NO, but had no effect on the production of the anti-inflammatory cytokine IL-10.
Bas
Esperanza
E
Departament de Farmacologia, Facultat de Farmàcia, Universitat de València, Av. Vicent Andrés Estellés s/n, 46100-Burjassot, Spain.
Recio
M Carmen
MC
Abdallah
Mohamed
M
Máñez
Salvador
S
Giner
Rosa M
RM
Cerdá-Nicolás
Miguel
M
Ríos
José-Luis
JL
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects / Q000276:immunology; D049109:Cell Proliferation; D004195:Disease Models, Animal; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D006027:Glycosides / Q000494:pharmacology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D018836:Inflammation Mediators / Q000378:metabolism; D057889:Iridoid Glycosides; D039823:Iridoids / Q000494:pharmacology*; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D010081:Oxazolone; D010835:Phytohemagglutinins; D028321:Plant Preparations / Q000737:chemistry / Q000494:pharmacology; D010946:Plants, Medicinal; D051381:Rats; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000276:immunology; D032266:Scrophularia / Q000737:chemistry*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000893:Anti-Inflammatory Agents; D006027:Glycosides; D018836:Inflammation Mediators; D057889:Iridoid Glycosides; D039823:Iridoids; D010835:Phytohemagglutinins; D028321:Plant Preparations; D011965:Receptors, Glucocorticoid; C115546:scrovalentinoside; D010081:Oxazolone